Novel cucurmosin‐based immunotoxin targeting programmed cell death 1‐ligand 1 with high potency against human tumor in vitro and in vivo-Reference-Cited by-同舟云学术

Novel cucurmosin‐based immunotoxin targeting programmed cell death 1‐ligand 1 with high potency against human tumor in vitro and in vivo

Published:2020-07-28 Issue:9 Volume:111 Page:3184-3194
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Zhang Caiyun¹^ORCID,Xiong Jiani¹²,Lan Yinxiang¹,Wu Jingyu¹,Wang Chengyan³,Huang Zhihong⁴,Lin Jizhen⁵,Xie Jieming¹

Affiliation:

1. Department of Pharmacology School of Pharmacy Fujian Provincial Key Laboratory of Natural Medicine Pharmacology Fujian Medical University Fuzhou China

2. Department of Medical Oncology Fujian Provincial Cancer HospitalFujian Medical University Cancer Hospital Fuzhou China

3. Institute of Laboratory Animal Center Fujian Medical University Fuzhou China

4. Public Technology Service Center Fujian Meidcal University Fuzhou China

5. The Cancer Center Union HospitalFujian Medical University Fuzhou China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Fujian Province

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14549

Reference41 articles.

1. Novel biotechnology approaches in colorectal cancer diagnosis and therapy

2. Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy

3. Immunotoxin: A new tool for cancer therapy

4. Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies

5. Immune Therapy for Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting;Critical Reviews in Oncology/Hematology;2024-10

2. Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology;Medical Oncology;2024-09-04

3. Cyclosporine A enhanced the cytotoxicity of immunotoxin to the HER-2-overexpressing SK-OV-3 cells;2023-07-26

4. Synthesis and Optimization of the Docetaxel-Loaded and Durvalumab-Targeted Human Serum Albumin Nanoparticles, In Vitro Characterization on Triple-Negative Breast Cancer Cells;ACS Omega;2023-07-13

5. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity;PLOS ONE;2023-06-07